106,668 Shares in Accelerate Diagnostics, Inc. (AXDX) Acquired by Strs Ohio
Strs Ohio purchased a new position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 106,668 shares of the medical research company’s stock, valued at approximately $2,394,000. Strs Ohio owned approximately 0.19% of Accelerate Diagnostics at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of AXDX. CLS Investments LLC purchased a new stake in Accelerate Diagnostics during the 2nd quarter valued at about $137,000. Legal & General Group Plc grew its position in Accelerate Diagnostics by 0.3% during the 1st quarter. Legal & General Group Plc now owns 5,123 shares of the medical research company’s stock valued at $123,000 after purchasing an additional 15 shares during the last quarter. SG Americas Securities LLC grew its position in Accelerate Diagnostics by 16.8% during the 1st quarter. SG Americas Securities LLC now owns 5,885 shares of the medical research company’s stock valued at $142,000 after purchasing an additional 846 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Accelerate Diagnostics during the 2nd quarter valued at about $228,000. Finally, UBS Asset Management Americas Inc. purchased a new stake in Accelerate Diagnostics during the 2nd quarter valued at about $243,000. Institutional investors own 44.63% of the company’s stock.
Accelerate Diagnostics (NASDAQ:AXDX) last posted its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.01). Accelerate Diagnostics had a negative net margin of 5,062.48% and a negative return on equity of 67.44%. The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.40 million.
Several brokerages recently commented on AXDX. ValuEngine downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. BidaskClub raised shares of Accelerate Diagnostics from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. BTIG Research reaffirmed a “buy” rating and set a $34.00 price target on shares of Accelerate Diagnostics in a report on Wednesday, July 12th. Finally, Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Three analysts have rated the stock with a sell rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $33.00.
In other news, insider Lawrence Mehren sold 223,215 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $22.40, for a total transaction of $5,000,016.00. Following the transaction, the insider now owns 762,381 shares in the company, valued at $17,077,334.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jack W. Schuler acquired 23,400 shares of the business’s stock in a transaction dated Monday, August 14th. The shares were bought at an average price of $21.35 per share, for a total transaction of $499,590.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 655,622 shares of company stock worth $13,251,092. Corporate insiders own 50.00% of the company’s stock.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics, Inc. (NASDAQ:AXDX).
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.